Business
Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022
(TheNewswire) LONDON, ONTARIO – TheNewswire - May 9, 2022 ...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n LONDON, ONTARIO –\n \n \n TheNewswire -\n \n \n May 9, 2022 – Sernova Corp. (TSXV:SVA)\n(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy\ntherapeutics company focused on developing a potential ‘functional\ncure’ for type 1 diabetes (T1D) and other chronic diseases, is\npleased to announce\n \n \n \n \n that that an abstract has been selected for an oral podium\npresentation at the upcoming American Diabetes Association (ADA)\n82\n \n \n nd\n \n \n Scientific Sessions, to be held from June 3-7, 2022, at the Ernest N.\nMorial Convention Center in New Orleans, LA.\n \n \n \n \n Abstract 306-OR:\n \n \n Modified Approach for Improved Islet Allotransplantation\ninto Prevascularized Sernova Cell Pouch\n \n \n TM\n \n \n Device:\nPreliminary Results of the Phase I/II Clinical Trial at University of\nChicago\n \n \n \n \n Abstract Session:\n \n \n Islet Transplantation —Basic Science\n \n \n \n \n Session Date/Time:\n \n Monday,\nJune 6, 2022 at 2:15 PM – 4:15 PM CT\n \n \n \n Presentation Time:\n \n 3:15-3:30\nPM CT\n \n \n \n Authors:\n \n Bachul PJ,\nPerez-Guetierrez A, Ling-jia Wang, Golab K, Basto L, Perea L, Tibudan\nM, Braden J, Thomas C, Philipson L, Barth R, Fung JJ, Witkowski P\n \n \n Sernova will disclose additional information about the presentation at\nthe time of the conference in alignment with the American Diabetes\nAssociation’s abstract embargo policies.\n \n \n \n ABOUT SERNOVA\n \n \n \n Sernova is developing regenerative medicine cell therapeutic solutions\nusing a medical  device (Cell Pouch) and immune protected therapeutic\ncells / tissues (i.e. human donor cells, corrected human cells and\nstem cell-derived cells) to improve the treatment and quality of life\nof people with chronic metabolic diseases such as insulin-dependent\ndiabetes, blood disorders including hemophilia, and other diseases\ntreated through cellular production of proteins or hormones missing or\nin short supply within the body. For more information, please visit\nwww.sernova.com.\n \n \n \n ABOUT SERNOVA’S CELL POUCH SYSTEM\nCELL THERAPY PLATFORM\n \n \n \n The Cell...